Lupin receives USFDA approval to market generic hypertension drug
Drug maker Lupin on Sunday said it has received approval from the US health regulator to market a generic hypertension drug in America.
The company has received approval from the US Food and Drug Administration (USFDA) for Propranolol Hydrochloride extended-release capsules in multiple strengths, Lupin Ltd said in a regulatory filing.
The company’s product is the generic version of ANI Pharmaceuticals’ Inderal LA extended-release capsules, it added.
The product will be manufactured at the company’s Pithampur-based manufacturing plant, the drug firm stated.
Propranolol Hydrochloride extended-release capsules USP are indicated in the management of hypertension.
They may be used alone or in combination with other antihypertensive agents, particularly a thiazide diuretic.
As per IQVIA MAT November 2023 data, Propranolol Hydrochloride extended-release capsules had estimated annual sales of USD 71 million in the US.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First Published: Jan 14 2024 | 5:18 PM IST